The Shockwave Javelin Peripheral IVL Catheter is the first forward intravascular lithotripsy (IVL) platform designed to modify calcium ahead of the catheter tip, enabling interventionists to cross heavily calcified peripheral artery disease (PAD) occlusions where a guidewire passes but balloons or stents cannot. By delivering spherical sonic pressure waves from a single distal emitter, the device cracks calcium in front of the catheter while gentle forward pressure is applied, eliminating the need for balloon inflation to deliver energy. One-year data from the FORWARD PAD study demonstrate durable performance with a 1.0% major amputation rate, 3.9% cardiovascular death rate, and 72.7% primary patency above the knee.

How Forward IVL Differs From Traditional Balloon IVL

Traditional peripheral IVL catheters require the balloon to be positioned within the calcified lesion and inflated to deliver shockwave energy. This approach fails when vessels are so stenotic or occluded that the balloon cannot cross or expand adequately. The Shockwave Javelin changes this workflow fundamentally.

Feature Traditional Peripheral IVL Shockwave Javelin Forward IVL
Energy delivery location Within balloon segment Beyond catheter tip (distal emitter)
Balloon inflation required for energy Yes No
Can cross occlusions where wire passes Limited Yes
Working length Varies by model 150 cm
Shockwave pulses per activation Varies Up to 120 pulses

The forward IVL platform delivers energy to calcium in front of the catheter, keeping procedures moving forward rather than requiring the device to sit inside the lesion. This distinction matters most in chronic total occlusions (CTOs) and subtotal occlusions with extreme narrowing, where conventional IVL catheters cannot even be positioned.

Clinical Workflow: Four Steps to Cross Calcified Lesions

The Javelin catheter follows a streamlined procedural sequence that integrates into existing endovascular practice patterns:

  1. Deliver to lesion – Advance the Shockwave Javelin to the calcified occlusion. No balloon inflation is necessary at this stage.

  2. Apply forward pressure with IVL activation – Generate sonic pressure waves while applying gentle forward pressure. The spherical energy cracks calcium ahead of the catheter tip.

  3. Continue calcium modification – Deliver additional IVL pulses until adequate calcium cracking is achieved to facilitate device passage.

  4. Proceed with definitive therapy – Once the lesion is crossed and modified, deliver the chosen treatment (balloon angioplasty, stenting, atherectomy, or additional IVL with other Shockwave catheters).

Also check:  How High-Speed Laser Hair Removal Increases Clinic Patient Throughput

This workflow eliminates the “cannot cross, cannot treat” bottleneck that traditionally forces clinicians to abandon endovascular approaches or resort to higher-risk surgical bypass.

FORWARD PAD Study: One-Year Safety and Efficacy Data

The FORWARD PAD IDE study provides the first prospective clinical evidence supporting the Shockwave Javelin in complex PAD lesions. Results presented at VIVA 2025 included high-risk patients with calcified occlusive disease above and below the knee.

Key 12-Month Outcomes

Endpoint Result
Technical acute procedural success 99%
Major adverse events at 30 days 1.1%
Target limb major amputation (12 months) 1.0%
Cardiovascular death (12 months) 3.9%
Clinically driven TLR (CD-TLR) 14.7%
Primary patency above-knee (1 year) 72.7%
Primary patency below-knee (1 year) 61.5%

The study demonstrated low rates of dissection (only one case), with no instances of perforation, abrupt closure, distal embolization, or no-reflow in final angiography. Principal Investigator Dr. JD Corl noted that “most patients remained free from repeat intervention,” indicating lasting durability in a complex population.

Indications and Anatomical Coverage

The Shockwave Javelin Peripheral IVL Catheter is intended for IVL-enabled modification and crossing of calcified lesions in the peripheral vasculature, including:

  • Iliac arteries

  • Femoral and iliofemoral arteries

  • Popliteal arteries

  • Infrapopliteal (below-knee) arteries

The device covers both above-the-knee (ATK) and below-the-knee (BTK) anatomy, making it suitable for critical limb ischemia (CLI) patients with distal disease. When combined with the existing Shockwave IVL portfolio (E8, L6, M5+, S4 catheters), physicians now have a comprehensive toolkit for calcified lesions across the entire peripheral tree.

When Shockwave Javelin Is the Right Tool

The Javelin catheter excels in specific clinical scenarios where traditional devices struggle:

Ideal use cases:

  • Chronic total occlusions where only a guidewire crosses

  • Extremely narrowed vessels (<3 mm) preventing balloon passage

  • Heavily calcified lesions resisting conventional crossing techniques

  • Situations requiring calcium modification before stent or balloon delivery

Also check:  What Are Precision Handpieces and Why Are They Essential in Modern Medical Aesthetic Treatments?

Less suitable scenarios:

  • Non-calcified lesions (IVL provides no benefit without calcium)

  • Lesions already accessible to standard balloon IVL catheters (may not require forward IVL)

  • Cases where surgical bypass is already indicated due to anatomy or patient factors

Interventionists should assess lesion calcification severity via intravascular ultrasound (IVUS) or angiographic grading before selecting Javelin over other IVL options.

Operational Limitations and Real-World Considerations

Even with strong clinical data, practitioners must understand the boundaries of forward IVL technology:

Expectation gaps: The Javelin modifies calcium to enable crossing, but it is not a standalone therapy. Definitive treatment (angioplasty, stenting, or additional IVL) is still required after calcium modification.

Component lifecycle: The catheter contains a single distal emitter with a finite pulse capacity (up to 120 shockwave pulses per activation). High-volume procedures may require multiple catheters, impacting procedure cost.

Training requirements: Forward IVL represents a workflow shift from traditional balloon IVL. Interventionists must adapt to applying forward pressure during energy delivery rather than inflating a balloon within the lesion.

Patient selection bias: The FORWARD PAD study enrolled high-risk, complex patients. Outcomes in lower-risk populations with less calcification may differ.

Cost considerations: As a newer technology, Javelin carries premium device pricing compared to established IVL catheters. Practices must weigh the value of crossing capability against per-procedure cost, particularly in value-based reimbursement environments.

Availability: The device received U.S. launch approval in March 2025. International availability may vary based on regulatory clearance timelines.

Integrating Javelin Into an Endovascular Practice

For vascular laboratories and interventional cardiology/vascular surgery practices, adding Javelin requires strategic consideration:

When to invest:

  • High volume of complex PAD cases with CTOs

  • Existing endovascular program seeking to reduce bypass surgery referrals

  • Practice already using Shockwave IVL (portfolio synergy with E8, L6, M5+, S4)

  • Need to expand below-knee intervention capabilities

Also check:  Candela Nordlys Platform: How One Multi-Application System Drives Medspa Expansion

When to wait or choose alternatives:

  • Low PAD volume where device cost per use is prohibitive

  • Practice primarily treating non-calcified or mildly calcified lesions

  • Budget constraints favoring established balloon IVL catheters

  • Limited access to Shockwave technical support or training

Practices should conduct a case-mix analysis before procurement, quantifying how many annual cases would benefit from forward IVL versus conventional approaches.

Frequently Asked Questions

What makes Shockwave Javelin different from other IVL catheters?
Javelin is the first forward IVL platform that delivers shockwave energy beyond the catheter tip via a single distal emitter, enabling calcium modification ahead of the device without balloon inflation. Traditional IVL requires the balloon to be positioned inside and inflated within the lesion.

Can Shockwave Javelin cross chronic total occlusions?
Yes, the device is specifically designed to cross calcified occlusions where a guidewire passes but balloons or other devices cannot, as demonstrated in the FORWARD PAD study.

What is the safety profile of Shockwave Javelin?
The FORWARD PAD study showed a 1.1% major adverse event rate at 30 days, 1.0% major amputation rate at 12 months, and no perforations or abrupt closures in the trial.

Does Javelin replace the need for balloon angioplasty or stenting?
No, Javelin modifies calcium to enable crossing and subsequent therapy. Definitive treatment (balloon, stent, atherectomy, or additional IVL) is still required after calcium modification.

Is Shockwave Javelin FDA approved?
Yes, Shockwave Medical launched the Javelin Peripheral IVL Catheter in the U.S. in March 2025 after meeting primary endpoints in the FORWARD PAD IDE study.

References

  1. Shockwave Javelin Peripheral IVL Catheter: A Deep Dive Into the Technology

  2. Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S.

  3. Johnson & Johnson One-Year Data Demonstrate Durable Performance and Safety of Shockwave Javelin

  4. J&J’s Shockwave Deal Pays Off as IVL Catheter Meets Primary Endpoint in Trial

  5. FORWARD PAD Results Presented for J&J’s Shockwave Javelin Peripheral IVL Catheter

  6. Shockwave Javelin Peripheral Product Page